Fiduciary Duties in a Clinical-Stage Context

Every corporate director owes fiduciary duties to the company and its shareholders. This is the foundation of corporate governance, and it applies equally whether you serve on the board of a Fortune 500 company or a twelve-person preclinical startup. The duties are the same. But what those duties require of you — the standard of care, the diligence expected, the conflicts you must navigate — is profoundly different in a clinical-stage biopharma company.

Understanding these differences is not an academic exercise. It is the difference between being a director who fulfills their obligations and one who exposes themselves to personal liability while believing they are doing everything right.

The Two Core Duties

Corporate law in most jurisdictions imposes two fundamental fiduciary duties on directors: the duty of care and the duty of loyalty.

The duty of care requires directors to make informed decisions. You must act with the level of care that a reasonably prudent person would exercise in a similar position. In practice, this means reading the materials, attending the meetings, asking questions, and making decisions based on adequate information. Courts generally protect directors who followed a reasonable process, even if the outcome was bad — this is the business judgment rule.

The duty of loyalty requires directors to act in the best interest of the company and its shareholders rather than in their own interest. You must not use your position for personal gain, must disclose conflicts of interest, and must not take corporate opportunities for yourself.

These duties sound straightforward. In a clinical-stage biopharma company, they are anything but.

Duty of Care in a World of Uncertainty

The duty of care requires informed decision-making. But in biopharma, the most consequential decisions involve uncertainty that no amount of diligence can eliminate. When the board votes to advance a program to Phase III, it is making a decision based on Phase II data that may or may not predict Phase III outcomes. The science is uncertain. The regulatory environment is uncertain. The competitive landscape is uncertain.

Does this mean the duty of care is impossible to fulfill? No. But it means the standard of care must be understood in context. A biopharma director fulfills their duty of care not by achieving certainty — that is impossible — but by ensuring that the process of decision-making is rigorous, that the information considered is as complete as reasonably available, and that the uncertainties are acknowledged and accounted for rather than ignored.

Concretely, this means several things.

You must understand the information you are voting on. This does not mean you must be a scientist. It means that when the board reviews clinical data, you must understand it well enough to ask informed questions and to evaluate whether management's interpretation is reasonable. If you do not understand the data, you have an obligation to seek clarification — from management, from independent experts, or from fellow directors — before you vote.

Directors who consistently vote on matters they do not understand are not protected by the business judgment rule. The rule requires that decisions be informed. A vote cast without understanding is, by definition, uninformed.

You must invest the time. Biopharma boards require more preparation time than boards in most other industries. The materials are more technical, the decisions are more complex, and the stakes are higher. If you are not willing to spend the time required to prepare for meetings, to read the scientific updates, to understand the financial model, and to stay current on the competitive landscape, you should not serve on a biopharma board.

The time commitment is particularly intense during periods when the company faces major decisions — trial go/no-go decisions, fundraising rounds, strategic transactions, or regulatory milestones. During these periods, the board may need to meet more frequently, and directors may need to be available on short notice. A director who is unreachable when the company is navigating a clinical hold or an unexpected acquisition approach is not fulfilling their duty of care.

You must seek independent information when warranted. The duty of care does not require directors to accept management's representations at face value in all circumstances. When the company faces a major decision, particularly one where management has a significant conflict or where the outcome is binary and high-stakes, the board should consider engaging independent advisors — financial, legal, scientific, or some combination — to provide an independent perspective.

This is not a vote of no confidence in management. It is a governance practice that protects the board, the company, and management itself. A board that relied on independent advice in making a major decision is in a far stronger legal position than one that relied solely on management's recommendation.

Duty of Loyalty in a Company Full of Conflicts

The duty of loyalty is especially complex in biopharma because the governance structure creates conflicts of interest that are structural rather than incidental.

Investor Director Conflicts

The most pervasive conflict in venture-backed biopharma is the position of investor directors. These directors represent investment funds that have specific return requirements, timeline pressures, and portfolio considerations. Their fund's interest and the company's interest are often aligned — both want the company to succeed. But they are not always aligned, and the moments of misalignment tend to coincide with the company's most important decisions.

When the company raises a new round of financing, investor directors who participate in the round have a direct financial interest in the terms. When the board evaluates an acquisition offer, investor directors may have preferences shaped by their fund's liquidity needs rather than the company's optimal strategy. When the board considers a pivot that would extend the company's timeline, investors nearing the end of their fund's life may resist even if the pivot is strategically sound.

Investor directors are legally obligated to fulfill their fiduciary duties to the company — not to their fund. In practice, this means they must disclose their conflicts, recuse themselves from votes where their fund has a direct interest that diverges from the company's interest, and support governance processes (such as independent director review of fundraising terms) that protect against conflicted decision-making.

Management Conflicts

The CEO and other executives who serve as officers have their own conflicts. Their compensation, career trajectory, and reputation are tied to the company's outcomes. This generally aligns their interests with the company's, but not always.

A CEO who has spent four years building a company around a single program may resist abandoning that program even when the data no longer supports it. A management team that has promised investors a Phase III trial start by year-end may feel pressure to proceed even when the team is not ready. These are real conflicts, and the board's duty of loyalty requires it to evaluate management's recommendations with an awareness of these pressures.

Independent Director Conflicts

Independent directors are not immune from conflicts. They may have consulting relationships with the company, personal relationships with other board members or executives, or professional interests that are affected by the company's decisions. The standard for independence requires not just the absence of financial conflicts but the absence of any relationship that would compromise the director's objective judgment.

In the small world of biopharma governance, maintaining true independence requires active vigilance. If you serve on multiple biopharma boards, you may encounter situations where the interests of one company conflict with another. If you have consulting relationships with companies in the same therapeutic space, your independence on any single board may be compromised. The duty of loyalty requires you to identify these situations proactively and to disclose them to the board even when disclosure is uncomfortable.

The Business Judgment Rule and Its Limits

The business judgment rule protects directors who make honest, informed decisions in good faith, even when those decisions turn out badly. This is critical in biopharma, where bad outcomes are common and often not the result of any governance failure. A Phase III trial can fail despite excellent governance, and the directors who approved the trial should not face liability for a scientific outcome they could not control.

But the business judgment rule has limits. It does not protect directors who were uninformed, who had undisclosed conflicts, who failed to exercise independent judgment, or who acted in bad faith. And courts in some jurisdictions have been willing to look closely at governance processes in biopharma companies, particularly when transactions involve conflicted parties or when shareholders allege that the board failed to consider alternatives.

The practical lesson is that process matters at least as much as outcome. A board that followed a rigorous process — that was informed, that considered alternatives, that engaged independent advisors when warranted, that documented its deliberations — is well-protected even if the decision it made turns out to be wrong. A board that skipped steps, ignored conflicts, or rubber-stamped management's recommendations is vulnerable even if the decision turns out well.

Practical Recommendations

Several practices help biopharma directors fulfill their fiduciary duties in the clinical-stage context.

Document your diligence. Board minutes should reflect the information the board considered, the questions that were asked, the alternatives that were discussed, and the basis for the decision. In biopharma, where decisions often involve complex scientific and financial considerations, detailed minutes are both a governance discipline and a legal protection.

Disclose conflicts early and often. The time to disclose a conflict is before it becomes an issue, not after someone discovers it. If you have a relationship, interest, or obligation that could be perceived as compromising your judgment on any matter before the board, disclose it. Let the board decide whether the conflict requires your recusal.

Know when to recuse. Recusal is not a sign of weakness. It is a sign of governance maturity. When you have a conflict that cannot be managed through disclosure alone, step out of the discussion and the vote. The board's decision will be stronger for it, and your position will be protected.

Ask the uncomfortable questions. The duty of care is not fulfilled by passive attendance. It is fulfilled by active engagement. If something does not make sense, say so. If the data does not support the recommendation, say so. If you believe the board is moving too fast or without adequate information, say so. The questions you did not ask are the ones that create liability.

Fiduciary duties in biopharma are not abstract legal concepts. They are practical obligations that shape how you prepare, how you engage, and how you vote. Take them seriously, and they will protect you. Treat them as formalities, and they will not.